News|Articles|January 25, 2019

Torrent Pharmaceuticals Limited Expands Recall

The company is voluntarily recalling six lots of Losartan potassium and hydrochlorothiazide tablets, USP because of the impurity, NDEA.

Torrent Pharmaceuticals Limited announced on Jan. 22, 2019 that it was expanding its voluntary recall from 10 lots of Losartan potassium tablets USP to include six lots of Losartan potassium and hydrochlorothiazide tablets, USP. The recall comes after trace amounts of N-nitrosodiethylamine (NDEA) were detected in API manufactured by Hetero Labs Limited.

According to the company, patients should continue to take their losartan, which is used to treat hypertension, because the risk to the patient’s health may be higher if they stop taking the medication without first discussing options with their physician. As of January 22, 2019, no adverse events had been reported in relation to the recalled products.

This recall joins a list of other products pulled off the market because of APIs containing NDEA. Both FDA and the European Medicines Agency have undergone investigations into the matter.

Source: FDA

 


Related to this article

Glass vial, pipette and woman scientist in laboratory for medical study, research or experiment. Test tube, dropper and professional female person with chemical liquid for pharmaceutical innovation. | Image Credit: ©HockleyMedia24/peopleimages.com -stock.adobe.com
Equivalence test using two one-sided tests are widely used for demonstrating the comparability of treatment effects in different research fields. The method described in the manuscript aims to use simulations in Microsoft Excel to compute power for 2 one-sided tests for two groups with unequal variances.
Complying with International Pharmacopoeias
Susan J. Schniepp, distinguished fellow with Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical, with Parexel, clear up some of the confusion about what does and does not need to be complied with regarding standards set by international pharmacopoeias.
CPHI Milan 2026: Nitrosamine Risk Mitigation, Part 2
Mitigating nitrosamine risk requires assessing each product individually, says Bram Baert, Global Head of Regulatory Affairs at Capsugel, and Sandrine Picco, Senior Analytical Specialist on Capsugel's Innovaform Accelerator Team, in this interview with PharmTech.